Aventis Pharma Q3 net seen at Rs 43.3cr: ICICI Sec

ALSO READ News and Notices about Aventis Pharma See interviews with Aventis Pharma Management See what other Experts & Brokerages are saying about Aventis Pharma See previous Results of Aventis Pharma Aventis Pharma BSE | NSE 10/02/12 Are Mutual Funds betting on Aventis Pharma?

Broking house, ICICI Securities estimates that Aventis Pharma 's net profit is expected to be at Rs 43.3 crore (Rs 433 million) in Q4CY06 versus Rs 42 crore (Rs 420 million) in the same period of last year, up 3.1% and revenues at Rs 212.6 crore (Rs 2.12 billion) compared to Rs 192.9 crore (Rs 1.92 billion), up 10.2% YoY.

It is bullish on Aventis Pharma and has recommended buy rating on the stock.

The ICICI Securities report on Aventis Pharma:

The report says, "After having declined in the past four quarters, exports would likely rise 8% YoY to Rs 552 million. They expect domestic dosage form sales to grow 9% YoY to Rs 1.7 billion driven by strong growth in core brands."

"EBITDA margin likely to decline 228bps to 26.1% mainly due to lower contribution from high-margin exports and rising staff costs on account of higher field force."

"Aventis continues to be one of the most profitable pharma MNCs operating in India and is well positioned to leverage opportunities arising post the IPR implementation."